AbbVie Inks a Deal With Neomorph

Neomorph, AbbVie strike $1.64 billion deal
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we see new data on a
AbbVie, Neomorph Strike Deal to Co-Develop Molecular Glue Degraders for Oncology, Immunology
Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion in milestone payments.
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based private biotech Neomorph to develop molecular glue degraders for multiple targets across oncology and immunology.
AbbVie and Neomorph enter molecular glue degrader partnership worth $1.64bn
AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and option-to-licence agreement combines AbbVie’s capabilities in oncology and immunology drug development with Neomorph’s molecular glue discovery platform.
Sticky, sticky, sticky: Neomorph tacks on another Big Pharma glue degrader deal with $1.6B AbbVie pact
Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. | Neomorph is building out its supply of Big Pharma partnerships,
AbbVie Teams Up With Neomorph for Molecular Glue Collab Worth up to $1.64B
Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.
AbbVie and Neomorph to codevelop molecular glue degraders for onchology
AbbVie (ABBV) and Neomorph announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple
On a dealmaking spree, AbbVie makes cancer, immunology pact with Neomorph
Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.
AbbVie, Neomorph partner on protein degrader drugs
NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of $299 billion, and Neomorph, Inc. have entered into a collaboration to develop a new class of drugs known as molecular glue degraders,
AbbVie To Collaborate With Neomorph To Develop Molecular Glue Degraders For Oncology And Immunology
AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular
AbbVie, Neomorph to develop molecular glue degraders
AbbVie (NYSE:ABBV) has entered into a collaboration agreement with Neomorph for the development of novel molecular glue degraders for multiple targets across oncology and immunology. Under the deal, Neomorph will receive an upfront payment and is eligible to receive up to $1.
Hosted on MSN2d
AbbVie and Neomorph link on oncology/immunology glue degraders
AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to ...
BioPharma Dive2d
Mixed results for Keytruda; AbbVie to work with Neomorph
Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...
AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology.
Hosted on MSN2d
Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug
J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.